标准化接受改善病情抗风湿药治疗的类风湿关节炎患者的健康结局:关于患者决策辅助工具与偏好研究的快速综述,为制定OMERACT健康结局描述符提供信息
该快速综述纳入11项患者决策辅助工具和27项患者偏好研究,评估7个类风湿关节炎结局在面向患者的英文描述中的呈现方式。结果显示同一结局的描述差异很大,缓解和疼痛等患者重要结局的描述很少,描述主要集中于症状领域(94%),其他领域覆盖较少(18-38%)。研究认为这些结局描述的异质性可为未来制定类风湿关节炎健康结局描述符提供参考。
要点
- 同一健康结局在不同患者决策辅助工具和偏好研究中的描述差异很大。
- 缓解和疼痛等患者重要结局在患者决策辅助工具和偏好研究中均很少被描述。
- 从健康结局描述符框架看,描述主要集中于症状领域(94%),其他领域覆盖较少(18-38%)。
核心结论
- 已发表的类风湿关节炎结局描述内容差异很大,且缺乏对常见患者重要结局的描述。
- 本研究详细概述了现有描述,可能为未来制定类风湿关节炎健康结局描述符提供信息。
研究设计与样本
- 对患者决策辅助工具和患者偏好研究进行快速综述,评估7个类风湿关节炎结局以英文向患者描述的方式。
- 7个结局由作者共识从一项关于类风湿关节炎药物治疗的活体系统综述中选取。
- 纳入11项患者决策辅助工具和27项患者偏好研究,经数据提取和主题内容分析后对每个结局提供叙述性总结。
主要发现
- 同一健康结局的描述在不同研究间差异很大。
- 不良事件在多数情况下被描述(N=26/38)。
- 患者决策辅助工具中缓解的描述为N=2/11,患者偏好研究中为N=1/27。
- 患者决策辅助工具中疼痛的描述为N=2/11,患者偏好研究中为N=6/27。
- 从健康结局描述符角度看,描述主要集中于患者可能经历的症状(94%),其他领域覆盖较少(18-38%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Interest in standardizing descriptions of health outcomes is increasing. In a Health Outcome Descriptor (HOD), outcomes are systematically described covering four domains: Symptoms, Time horizon, Testing and Treatment, and Consequences. Given the lack of HODs for Rheumatoid Arthritis (RA), the aim of this study was to review published RA outcome descriptions and map them to the HOD framework. METHODS: We conducted a rapid review of patient-decision aids (PtDAs) and patient preference studies to assess how seven RA outcomes have been described in English to patients. These outcomes were selected by author consensus, from a living systematic review of RA drug therapy. After data extraction and a thematic content analysis, a narrative summary for each outcome was provided. RESULTS: We included 11 PtDAs and 27 patient preference studies. Overall, the descriptions of the same health outcome varied widely across studies. Adverse events (AEs) were described in most cases (N = 26/38). For both PtDAs and preference studies, few provided a description for patient-important outcomes like remission (N = 2/11 and N = 1/27 respectively) and pain (N = 2/11 and N = 6/27 respectively). From an HOD perspective, the descriptions focused primarily on symptoms patients may experience (94 %), and less on the other domains (18-38 %). CONCLUSION: There is wide variability in the content of the published RA outcome descriptions, as well as a lack of descriptions regarding common patient-important outcomes. As this study provides a detailed overview of existing descriptions, it may inform future development of HODs for RA.
引用
- Raskin N, Hiligsmann M, Rebutoc AR, et al. Standardizing health outcomes for people with rheumatoid arthritis receiving disease modifying drug therapy: A rapid review of patient-decision aids and preference studies to inform the development of OMERACT Health Outcome Descriptors. Semin Arthritis Rheum. 2025. PMID: 40544704. doi:10.1016/j.semarthrit.2025.152769
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。